Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 5Phase 3 4Phase 1 2

Status

Recruiting 6Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 1

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 5Gynecologic 2Sarcoma 1

Conditions

Breast Neoplasms 3Sarcoma, Endometrial Stromal 1Recurrence 1Perivascular Epithelioid Cell Neoplasms 1Endometrial Neoplasms 1ER+ Breast Cancer 1Carcinoma, Intraductal, Noninfiltrating 1Adenosarcoma of the uterus 1

Interventions

Specimen Handling 273Magnetic Resonance Spectroscopy 224pembrolizumab 214Carboplatin 173Biopsy 166Cisplatin 159Nivolumab 149Cyclophosphamide 133Radiotherapy 117Paclitaxel 117Gemcitabine 112Bevacizumab 92durvalumab 86Dexamethasone 80Rituximab 76Oxaliplatin 73atezolizumab 68Capecitabine 67venetoclax 66Fluorouracil 66Doxorubicin 65Docetaxel 65Etoposide 63Radiosurgery 60Radiation 57Prednisone 57Cytarabine 56Ipilimumab 55Pemetrexed 54Taxes 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × elacestrant × 90 days × Clear all
NCT06075953 2026-05-22

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
400 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT07209449 2026-05-22

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
75 enrolled
Gynecologic

Recurrence, Endometrial Neoplasms

NCT07467772 2026-05-22

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Dana-Farber Cancer Institute

Phase 2 Recruiting
30 enrolled
GynecologicSarcoma

Adenosarcoma of the uterus, Sarcoma, Endometrial Stromal, Perivascular Epithelioid Cell Neoplasms

NCT07395336 2026-05-14

COMBINE-01

European Institute of Oncology

Phase 2 Recruiting
26 enrolled
Breast

Breast Neoplasms

NCT06923527 2026-05-12

Circulating Tumor DNA

Yale University

Phase 2 Recruiting
50 enrolled
Breast

ER+ Breast Cancer

NCT05596409 2026-05-07

ELCIN

Stemline Therapeutics, Inc.

Phase 2 Active not recruiting
61 enrolled
Breast

Breast Neoplasms

NCT05982093 2026-04-24

SOLTI-2104

SOLTI Breast Cancer Research Group

Phase 2 Recruiting
96 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡